IntroductionWith a population-based cohort in the VATS era, we aimed to evaluate the value of stair-climbing test (SCT) on short- and long-term outcomes of lung cancer surgery.MethodsAll patients operated due to primary lung cancer in Central Finland and Ostrobothnia from 2013 to June 2020 were included. For the analysis, clinical variables including the outcome of SCT and cause-specific mortality were available. Short- and long-term outcomes were compared between <11 m (n=66) and >12 m SCT (n=217) groups.ResultsPatients with poor performance (<11 m) had more comorbidities and worse lung function but did not differ in tumor stage or treatment. No differences between groups were observed in major morbidity rate (10.6% versus 11.1%, p=0.918) or median hospital stay (5 (IQR 4–7) versus 4 (IQR 3–7), p=0.179). At 1-year, fewer patients were alive and living at home in <11 m group (81.3%) compared to >12 m group (94.2%), p=0.002. No difference was observed in cancer-specific 5-year survival. Non-cancer-specific survival (62.9% versus 83.1%, p<0.001) and overall survival (49.9% versus 70.0%, p<0.001) were worse in <11 m group. After adjustment for confounding factors, SCT remained as a significant predictor for non-cancer-specific (4.28; 95%CI 2.10 to 8.73) and overall mortality (2.38; 95%CI 1.43 to 3.98).ConclusionsWith SCT-based exercise testing, VATS can be performed safely, with similar major morbidity rate in poor performance group (<11 m) compared to >12 m group. Poor exercise performance increases non-cancer-specific mortality. Being a major predictor of survival, exercise capacity should be included in prognostic models.